Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.

PURPOSE There is a need to better understand prostate cancer progression and identify new prognostic markers for this tumor. We investigated the association between promoter methylation in a priori selected genes and survival in two independent large series of prostate cancer patients. METHODS We followed up with two cohorts of patients (216 patients diagnosed in 1982 to 1988 and 243 patients diagnosed in 1993 to 1996) diagnosed at one hospital pathology ward in Turin, Italy. DNA was obtained from paraffin-embedded tumor tissues and evaluated for promoter methylation status in glutathione S-transferase (GSTP1), adenomatous polyposis coli (APC), and runt-related transcription factor 3 (RUNX3). Results The two cohorts had different prevalences of methylation in APC (P = .047), GSTP1 (P = .002), and RUNX3 (P < .001). Methylation in APC was associated with an increased risk of prostate cancer-specific mortality (hazard ratio [HR] = 1.42; 95% CI, 0.98 to 2.07 in the 1980s cohort; HR = 1.57; 95% CI, 0.95 to 2.62 in the 1990s cohort; HR = 1.49; 95% CI, 1.11 to 2.00 in the two cohorts combined). In subgroup analyses, the HRs were higher among patients with a Gleason score less than 8 (HR = 1.52; 95% CI, 0.85 to 2.73 in the 1980s cohort; HR = 2.09; 95% CI, 1.02 to 4.28 in the 1990s cohort). Methylation in RUNX3 was associated with prostate cancer mortality only in the 1990s cohort, and methylation in GSTP1 did not predict mortality in either cohort. CONCLUSION The pattern of hypermethylation may have changed after the introduction of prostate-specific antigen testing in the beginning of the 1990s. Promoter methylation in APC was identified as a marker for prostate cancer progression.

[1]  A. Partin,et al.  Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy , 2005, Clinical Cancer Research.

[2]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[3]  M. Kattan,et al.  Nomograms for prostate cancer , 2006, BJU international.

[4]  P. Horák,et al.  Promoter hypermethylation of GSTP1, AR, and 14‐3‐3σ in serum of prostate cancer patients and its clinical relevance , 2007, The Prostate.

[5]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[6]  Zijie Sun,et al.  Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. , 2006, Cancer letters.

[7]  Michael W Kattan,et al.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Esteller.  CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future , 2002, Oncogene.

[9]  P. Carroll,et al.  Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma , 2006, Cancer.

[10]  A. Carvalho,et al.  High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients , 2007, Clinical Cancer Research.

[11]  Ian M Thompson,et al.  Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.

[12]  J. Minna,et al.  Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  L. Holmberg,et al.  Prostate-specific antigen levels as a predictor of lethal prostate cancer. , 2007, Journal of the National Cancer Institute.

[14]  J. Epstein,et al.  Optimal Use of a Panel of Methylation Markers with GSTP1 Hypermethylation in the Diagnosis of Prostate Adenocarcinoma , 2004, Clinical Cancer Research.

[15]  N. Cho,et al.  Hypermethylation of CpG island loci and hypomethylation of LINE‐1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features , 2007, The Journal of pathology.

[16]  J. Ferlay,et al.  Globocan 2000 : cancer incidence, mortality and prevalence worldwide , 2001 .

[17]  John D Minna,et al.  Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  P. Armitage,et al.  Statistical methods in medical research , 1971 .

[19]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[20]  Zijie Sun,et al.  Roles and regulation of Wnt signaling and β-catenin in prostate cancer , 2006 .

[21]  K. Biermann,et al.  CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. , 2008, Urology.

[22]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[23]  A. D. De Marzo,et al.  Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. , 2004, European urology.

[24]  R. Dikshit,et al.  Efficient DNA extraction from 25‐year‐old paraffin‐embedded tissues: study of 365 samples , 2007, Pathology.

[25]  L. Bisanti,et al.  Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in a metropolitan area of northern Italy , 2002, Journal of medical screening.

[26]  M. Esteller.  Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[27]  D. Bostwick,et al.  Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. , 2007, Pathology.

[28]  M. Graefen,et al.  Role of nomograms for prostate cancer in 2007 , 2007, World Journal of Urology.

[29]  P. Carroll,et al.  Ethnic group‐related differences in CpG hypermethylation of the GSTP1 gene promoter among African‐American, Caucasian and Asian patients with prostate cancer , 2005, International journal of cancer.

[30]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .

[31]  A. Wellmann,et al.  Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci , 2005, Clinical Cancer Research.

[32]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[33]  R. Dikshit,et al.  Hypermethylation, risk factors, clinical characteristics, and survival in 235 patients with laryngeal and hypopharyngeal cancers , 2007, Cancer.

[34]  J. Ellinger,et al.  Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. , 2007, European urology.

[35]  M. Hoque,et al.  A Quantitative Promoter Methylation Profile of Prostate Cancer , 2004, Clinical Cancer Research.

[36]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[37]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[38]  J. Minna,et al.  Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. , 2001, Cancer research.

[39]  Jeanne Kowalski,et al.  Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer , 2004, Cancer Research.

[40]  P. Carroll,et al.  Multigene Methylation Analysis for Detection and Staging of Prostate Cancer , 2005, Clinical Cancer Research.

[41]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[42]  P. Walsh,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 2000, The Journal of urology.

[43]  S. Nishizuka,et al.  Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia , 2000, Oncogene.

[44]  F. Bray,et al.  Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. , 2007, Journal of the National Cancer Institute.

[45]  Klaus Jung,et al.  Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. , 2007, The Journal of urology.

[46]  A. Perry,et al.  The emerging roles of DNA methylation in the clinical management of prostate cancer. , 2006, Endocrine-related cancer.

[47]  B. Trock,et al.  Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy , 2005, Clinical Cancer Research.

[48]  C. D. de Mola,et al.  Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database , 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[49]  Hyeon Joo Lee,et al.  Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia , 2004, The Journal of pathology.

[50]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.